14 results on '"Behre, Gerhard"'
Search Results
2. MicroRNA Expression Patterns Reveal a Role of the TGF-β Family Signaling in AML Chemo-Resistance.
- Author
-
Reichelt, Paula, Bernhart, Stephan, Wilke, Franziska, Schwind, Sebastian, Cross, Michael, Platzbecker, Uwe, and Behre, Gerhard
- Subjects
RNA metabolism ,TRANSFORMING growth factors-beta ,BIOMARKERS ,CANCER chemotherapy ,CELLULAR signal transduction ,CANCER patients ,BIOINFORMATICS ,GENE expression ,GENES ,GENE expression profiling ,RESEARCH funding ,CYTARABINE ,DRUG resistance in cancer cells ,LONGITUDINAL method ,TRANSLATIONS ,OVERALL survival - Abstract
Simple Summary: In patients with acute myeloid leukemia (AML), cytarabine-based chemotherapy usually achieves remission, but this is commonly followed by relapse and chemo-resistance. In this study, we aim to establish next-generation sequencing (NGS)-based microRNA expression profiling and pathway analysis to identify pathways regulated differentially between chemo-sensitive and -resistant AML as potential therapeutic targets. MicroRNA expression profiles differ significantly between chemo-sensitive and chemo-resistant AML cells and reflect differences in the activity of intracellular signaling cascades. Alterations in signaling pathway activities contribute to treatment resistance and thus represent potential drug targets. Our microRNA-led approach indicates a role for activin receptor type 2A in ARA-C resistance of AML cells and suggests activin receptor signaling to be a candidate pathway for targeted therapy. Resistance to chemotherapy is ultimately responsible for the majority of AML-related deaths, making the identification of resistance pathways a high priority. Transcriptomics approaches can be used to identify genes regulated at the level of transcription or mRNA stability but miss microRNA-mediated changes in translation, which are known to play a role in chemo-resistance. To address this, we compared miRNA profiles in paired chemo-sensitive and chemo-resistant subclones of HL60 cells and used a bioinformatics approach to predict affected pathways. From a total of 38 KEGG pathways implicated, TGF-β/activin family signaling was selected for further study. Chemo-resistant HL60 cells showed an increased TGF-β response but were not rendered chemo-sensitive by specific inhibitors. Differential pathway expression in primary AML samples was then investigated at the RNA level using publically available gene expression data in the TGCA database and by longitudinal analysis of pre- and post-resistance samples available from a limited number of patients. This confirmed differential expression and activity of the TGF-β family signaling pathway upon relapse and revealed that the expression of TGF-β and activin signaling genes at diagnosis was associated with overall survival. Our focus on a matched pair of cytarabine sensitive and resistant sublines to identify miRNAs that are associated specifically with resistance, coupled with the use of pathway analysis to rank predicted targets, has thus identified the activin/TGF-β signaling cascade as a potential target for overcoming resistance in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia
- Author
-
Hilger, Nadja, Müller, Claudia, Stahl, Lilly, Müller, Anne M., Zoennchen, Bianca, Dluczek, Sarah, Halbich, Christoph, Wickenhauser, Claudia, Gerloff, Dennis, Wurm, Alexander A., Behre, Gerhard, Kretschmer, Anna, Fricke, Stephan, and Publica
- Subjects
Immunology ,Graft vs Host Disease ,Apoptosis ,Graft vs Leukemia Effect ,acute myeloid leukemia ,Mice ,immune system diseases ,hemic and lymphatic diseases ,Animals ,Humans ,Transplantation, Homologous ,Original Research ,anti-human CD4 antibody MAX.16H5 ,Mice, Knockout ,graft-vs.-host disease ,Hematopoietic Stem Cell Transplantation ,graft-vs.-leukemia ,Flow Cytometry ,Prognosis ,Disease Models, Animal ,Leukemia, Myeloid, Acute ,surgical procedures, operative ,fms-Like Tyrosine Kinase 3 ,C3H / HeN ,Immunoglobulin G ,C3H/HeN ,CD4 Antigens ,32D-FLT3ITD - Abstract
Despite the constant development of innovative therapeutic options for hematological malignancies, the gold-standard therapy regimen for curative treatment often includes allogeneic hematopoietic stem cell transplantation (HSCT). The graft-vs.-leukemia effect (GVL) is one of the main therapeutic goals that arises from HSCT. On the other hand, graft-vs.-host disease (GVHD) is still one of the main and most serious complications following allogeneic HSCT. In acute myeloid leukemia (AML), HSCT together with high-dose chemotherapy is used as a treatment option. An aggressive progression of the disease, a decreased response to treatment, and a poor prognosis are connected to internal tandem duplication (ITD) mutations in the Fms like tyrosine kinase 3 (FLT3) gene, which affects around 30% of AML patients. In this study, C3H/HeN mice received an allogeneic graft together with 32D-FLT3ITD AML cells to induce acute GVHD and GVL. It was examined if pre-incubation of the graft with the anti-human cluster of differentiation (CD) 4 antibody MAX.16H5 IgG1 prevented the development of GVHD and whether the graft function was impaired. Animals receiving grafts pre-incubated with the antibody together with FLT3ITD AML cells survived significantly longer than mice receiving untreated grafts. The observed prolonged survival due to MAX.16H5 incubation of immune cell grafts prior to transplantation may allow an extended application of additional targeted strategies in the treatment of AML.
- Published
- 2018
4. Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible.
- Author
-
Vucinic, Vladan, Jentzsch, Madlen, Schwind, Sebastian, Bach, Enrica, Leiblein, Sabine, Remane, Yvonne, Rieprecht, Susanne, Otto, Sandra, Kubasch, Anne-Sophie, Behre, Gerhard, Cross, Michael, Platzbecker, Uwe, and Franke, Georg-Nikolaus
- Subjects
ACUTE myeloid leukemia ,STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation - Abstract
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and treatment-related acute myeloid leukemia (tAML) after chemotherapy or radiation therapy for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the cases of four consecutive patients with AML-MRC or tAML who received CPX-351 as outpatient induction therapy immediately followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in complete remission and one in partial remission) and two patients received allo-HSCT in aplasia (one at 11 days and one at 52 days after the start of induction therapy with CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are alive and two are in remission. Further studies will help define and expand the role of CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to undergo allo-HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
- Author
-
Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, and Ostermann, Helmut
- Subjects
HEMATOLOGIC malignancies ,COMMUNICABLE disease treatment ,MYCOSES ,ANTIFUNGAL agents ,IMMUNOCOMPROMISED patients ,AMPHOTERICIN B ,NEUTROPENIA ,ONCOLOGY ,PATIENTS ,PREVENTION ,THERAPEUTICS ,SOCIETIES ,ACUTE myeloid leukemia treatment ,MYELODYSPLASTIC syndromes treatment ,HETEROCYCLIC compounds ,VORICONAZOLE ,CLINICAL trials ,DRUG monitoring ,HEMATOLOGY ,HEMATOPOIETIC stem cell transplantation ,MEDICAL societies ,MYELODYSPLASTIC syndromes ,PREVENTIVE health services ,ACUTE myeloid leukemia - Abstract
Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. The Janus-faced Nature of miR-22 in Hematopoiesis: Is It an Oncogenic Tumor Suppressor or Rather a Tumor-Suppressive Oncogene?
- Author
-
Wurm, Alexander Arthur, Behre, Gerhard, and Tenen, Daniel G.
- Subjects
- *
MICRORNA , *HEMATOPOIESIS , *TUMOR suppressor genes , *ONCOGENES , *DRUG approval - Abstract
The article discusses the application of the micro-RNA molecule miR-22 in Hematopoiesis. It discusses its application with regard to it being an oncogenic tumor suppressor or a tumor-suppressive oncogene. Topics discussed include research studies with regard to the matter, discoveries of micro-RNAs and approval of drugs based on micro-RNA.
- Published
- 2017
- Full Text
- View/download PDF
7. CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation.
- Author
-
Federzoni, Elena A., Humbert, Magali, Torbett, Bruce E., Behre, Gerhard, Fey, Martin F., and Tschan, Mario P.
- Subjects
CARRIER proteins ,ACUTE myeloid leukemia ,NEUTROPHILS ,GLUCOKINASE ,KRUPPEL-like factors ,TRETINOIN ,GENETICS - Abstract
The basic leucine zipper transcription factor CCAAT/enhancer binding protein alpha (CEBPA) codes for a critical regulator during neutrophil differentiation. Aberrant expression or function of this protein contributes to the development of acute myeloid leukemia (AML). In this study, we identified two novel unrelated CEBPA target genes, the glycolytic enzyme hexokinase 3 (HK3) and the kru'ppel-like factor 5 (KLF5) transcription factor, by comparing gene profiles in two cohorts of CEBPA wild-type and mutant AML patients. In addition, we found CEBPA-dependent activation of HK3 and KLF5 transcription during all-trans retinoic acid (ATRA) mediated neutrophil differentiation of acute promyelocytic leukemia (APL) cells. Moreover, we observed direct regulation of HK3 by CEBPA, whereas our data suggest an indirect regulation of KLF5 by this transcription factor. Altogether, our data provide an explanation for low HK3 and KLF5 expression in particular AML subtype and establish these genes as novel CEBPA targets during neutrophil differentiation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. The actin-binding protein CORO1A is a novel PU.1 ( SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients.
- Author
-
Federzoni, Elena A., Humbert, Magali, Valk, Peter J. M., Behre, Gerhard, Leibundgut, Elisabeth O., Torbett, Bruce E., Fey, Martin F., and Tschan, Mario P.
- Subjects
TRANSCRIPTION factors ,HEMATOPOIESIS ,MICROFILAMENT proteins ,ACUTE promyelocytic leukemia ,ACUTE myeloid leukemia ,HEMATOLOGY - Abstract
This article discusses a study which identified the haematopoietic transcription factors PU.1 and CEBPA as transcriptional regulators of the actin-binding protein CORO1A in patients with acute promyelocytic leukemia (APL) and acute myeloid leukemia (AML). Researchers found that significantly lower CORO1A levels were found in APL and in CEBPA-mutated AML patient samples. They also learned that inhibiting CORO1A markedly impaired neutrophil differentiation of APL cells.
- Published
- 2013
- Full Text
- View/download PDF
9. Proteomics of AML1/ETO Target Proteins: AML1–ETO Targets a C/EBP–NM23 Pathway.
- Author
-
Singh, Sheo Mohan, Trivedi, Arun Kumar, Lochab, Savita, Christopeit, Maximilian, Hiddemann, Wolfgang, and Behre, Gerhard
- Subjects
PROTEOMICS ,ACUTE myeloid leukemia ,GEL electrophoresis ,MASS spectrometry ,ANNEXINS ,CANCER ,BIOLOGY - Abstract
Introduction: The rational design of targeted therapies for acute myeloid leukemia (AML) requires the discovery of novel protein pathways in the systems biology of a specific AML subtype. We have shown that in the AML subtype with translocation t(8;21), the leukemic fusion protein AML1–ETO inhibits the function of transcription factors PU.1 and C/EBPα via direct protein–protein interaction. In addition, recently using proteomics, we have also shown that the AML subtypes differ in their proteome, interactome, and post-translational modifications. Methods: We, therefore, hypothesized that the systematic identification of target proteins of AML1–ETO on a global proteome-wide level will lead to novel insights into the systems biology of t(8;21) AML on a post-genomic functional level. Thus, 6 h after inducible expression of AML1–ETO, protein expression changes were identified by two-dimensional gel electrophoresis and subsequent mass spectrometry analysis. Results: Twenty-eight target proteins of AML1–ETO including prohibitin, NM23, HSP27, and Annexin1 were identified by MALDI-TOF mass spectrometry. AML1–ETO upregulated the differentiation inhibitory factor NM23 protein expression after 6 h, and the NM23 mRNA expression was also elevated in t(8;21) AML patient samples in comparison with normal bone marrow. AML1–ETO inhibited the ability of C/EBP transcription factors to downregulate the NM23 promoter. These data suggest a model in which AML1–ETO inhibits the C/EBP-induced downregulation of the NM23 promoter and thereby increases the protein level of differentiation inhibitory factor NM23. Conclusions: Proteomic pathway discovery can identify novel functional pathways in AML, such as the AML1–ETO–C/EBP–NM23 pathway, as the main step towards a systems biology and therapy of AML. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
10. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
- Author
-
Elsässer, Annika, Franzen, Michael, Kohlmann, Alexander, Weisser, Martin, Schnittger, Susanne, Schoch, Claudia, Reddy, Venkateshwar A, Burel, Sebastian, Zhang, Dong-Er, Ueffing, Marius, Tenen, Daniel G, Hiddemann, Wolfgang, and Behre, Gerhard
- Subjects
ONCOGENES ,ACUTE myeloid leukemia ,BONE marrow cells ,MESSENGER RNA ,PROMOTERS (Genetics) - Abstract
Overexpression of proto-oncogene c-jun and constitutive activation of the Jun N-terminal kinase (JNK) signaling pathway have been implicated in the leukemic transformation process. However, c-jun expression and the role of the JNK signaling pathway have not been investigated in primary acute myeloid leukemia (AML) cells with frequently observed balanced rearrangements such as t(8;21). In the present study, we report elevated c-jun mRNA expression in AML patient bone marrow cells with t(8;21), t(15;17) or inv(16), and a high correlation in mRNA expression levels of AML1-ETO and c-jun within t(8;21)-positive AML patient cells. In myeloid U937 cells, c-jun mRNA and protein expression increase upon inducible expression of AML1-ETO. AML1-ETO transactivates the human c-jun promoter through the proximal activator protein (AP-1) site by activating the JNK pathway. Overexpression of JNK-inhibitor JIP-1 and chemical JNK inhibitors reduce the transactivation capacity of AML1-ETO on the c-jun promoter and the proapoptotic function of AML1-ETO in U937 cells. An autocrine mechanism involving granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor (G-CSF-R) might participate in AML1-ETO mediated JNK-signaling, because AML1-ETO induces G-CSF and G-CSF-R expression, and G-CSF-R-neutralizing antibodies reduce AML1-ETO-induced JNK phosphorylation. These data suggest a model in which AML1-ETO induces proto-oncogene c-jun expression via the proximal AP-1 site of the c-jun promoter in a JNK-dependent manner.Oncogene (2003) 22, 5646-5657. doi:10.1038/sj.onc.1206673 [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
11. Cytogenetics detects infiltrations of a primary cutaneous acute myeloid leukemia to the kidney.
- Author
-
Christopeit, Maximilian, Mueller, Lutz Peter, Hainz, Michael, Holzhausen, Hans-Jürgen, and Behre, Gerhard
- Subjects
ACUTE myeloid leukemia ,RENAL cancer ,HISTOLOGY ,TOMOGRAPHY ,IN situ hybridization ,CYTOGENETICS - Abstract
Extramedullary manifestations of acute myeloid leukemia (AML) are rare and commonly involve one tissue. We report of a cutaneous acute myelomonocytic leukemia infiltrating the kidney next to the skin. A 61-year-old female patient with complex karyotype cutaneous AML FAB M4 underwent abdominal computed tomography scans. A lesion in her left kidney appeared suspicious of renal carcinoma as confirmed by histology. However, fluorescence in situ hybridization cytogenetics revealed a chromosome 11q23 abnormality in the nephrectomy specimen, which also appeared in the leukemic blasts of skin and bone marrow. Closer histomorphologic workup revealed an infiltration of the kidney with leukemia. This case report illustrates how modern diagnostic procedures can help to reveal rare sites of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
12. C/EBPα S248A mutation reduces granulocytic differentiation in human leukemic K562 cells
- Author
-
Singh, Sheo M., Trivedi, A.K., and Behre, Gerhard
- Subjects
- *
CELL differentiation , *MICROBIAL mutation , *CANCER cells , *PHOSPHORYLATION - Abstract
Abstract: Phosphorylation of C/EBPα can either lead to granulocytic differentiation or a block in granulopoiesis. This dichotomy in effect is dependent on the upstream signaling pathway and the phosphorylation site in C/EBPα. Ras signaling induced phosphorylation of S248 residue of C/EBPα is known to enhance granulocytic differentiation. In this study, using β-estradiol inducible stable cell lines we show that the point mutation of phosphorylation site S248 in C/EBP disrupts the CD11b and GCSFr expression and subsequently reduces the differentiation of leukemic K562 cells. Based on our observations in the present study, we conclude that S248A mutation of C/EBPα leads to a reduction of granulocytic differentiation markers and a block in differentiation at the morphological level. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
13. Pretreatment CD34+/CD38– Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation.
- Author
-
Jentzsch, Madlen, Geus, Ulrike, Grimm, Juliane, Vucinic, Vladan, Pönisch, Wolfram, Franke, Georg-Nikolaus, Behre, Gerhard, Niederwieser, Dietger, and Schwind, Sebastian
- Subjects
- *
STEM cell transplantation , *MYELODYSPLASTIC syndromes , *HEMATOPOIETIC stem cell transplantation , *CYTOGENETICS , *BONE marrow cells , *ACUTE myeloid leukemia - Abstract
• High CD34+CD38– cells are associated with adverse genetic risk and blast excess in MDS patients. • High CD34+CD38– cells identify MDS patients with poor outcome after HSCT. • High CD34+CD38– cells allow risk stratification additionally to the IPSS-R. Myelodysplastic syndrome (MDS) is a highly heterogeneous clonal hematopoietic disorder. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment and is of particular interest in patients at high risk for progression to acute myeloid leukemia (AML). In MDS, CD34+/CD38– cells possess MDS stem cell potential, and secondary AML (sAML) clones originate from the MDS disease stage. However, the prognostic impact of the pretreatment stem cell population burden in MDS remains unknown. We retrospectively analyzed the prognostic impact of the pretreatment CD34+/CD38– cell burden in 124 MDS patients who received allogeneic HSCT at our institution. A high pretreatment bone marrow CD34+/CD38– cell burden (≥1%) was associated with worse genetic risk and a higher incidence of blast excess. Patients with a high CD34+/CD38– cell burden had a significantly higher cumulative incidence of MDS relapse, a higher cumulative incidence of secondary AML, and a trend for shorter overall survival after allogeneic HSCT. In multivariable analyses this prognostic impact was shown to be independent of other clinical and cytogenetic risk factors in MDS. Patients suffering MDS relapse or progression to AML also had a higher pre-treatment CD34+/CD38– cell burden as a continuous variable. The observed prognostic impact is likely mediated by MDS stem cells within the CD34+/CD38– cell population initiating MDS relapse or progression to AML. New therapeutic strategies targeting MDS stem cells might improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
- Author
-
Katzerke, Christiane, Madan, Vikas, Gerloff, Dennis, Bräuer-Hartmann,, Daniela, Hartmann, Jens-Uwe, Wurm, Alexander Arthur, Müller-Tidow, Carsten, Schnittger, Susanne, Tenen, Daniel G., Niederwieser, Dietger, and Behre, Gerhard
- Subjects
- *
ACUTE myeloid leukemia , *TRANSCRIPTION factors , *BONE marrow cells , *HEMATOPOIETIC system , *BIOMARKERS - Abstract
The transcription factor CCAAT enhancer binding protein a (C/EBPα) is a master regulator in granulopoiesis and is frequently disrupted in acute myeloid leukemia (AML). We have previously shown that C/EBPa exerts its effects by regulating microRNAs (miRs) such as miR-223 and miR-34a. Here, we confirm miR-30c as a novel important target of C/EBPα during granulopoiesis. Thus, wild-type C/EBPα-p42 directly upregulates miR-30c expression, whereas C/EBPα-p30, found in AML, does not. miR-30c is downregulated in AML, especially in normal karyotype AML patients with CEBPA mutations. An induced C/EBPα knockout in mice leads to a significant downregulation of miR-30c expression in bone marrow cells. We identified NOTCH1 as a direct target of miR-30c. Finally, a block of miR- 30c prevents C/EBPα-induced downregulation of Notchl protein and leads to a reduced CD11b expression in myeloid differentiation. Our study presents the first evidence that C/EBPα, miR-30c, and Notchl together play a critical role in granulocytic differentiation and AML, and particularly in AML with CEBPA mutations. These data reveal the importance of deregulated miRNA expression in leukemia and may provide novel biomarkers and therapeutic targets in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.